SummaryWe determined plasma apolipoprotein H (/~2-glycoprotein I) levels in 300 healthy adult individuals and evaluated the frequencies of the Bg N and Bg D alleles in a Japanese population. These results were then compared with the previous reports. The plasma apo H levels in the subjects showed bimodal distribution: 274 subjects were in the range 15.6-33.2 mg/dl and were considered to be homozygous for Bg N (phenotype NN), and 26 subjects were found in the range 9.6-14.8 mg/dl and were presumably heterozygous for Bg N and Bg D (phenotype ND). In this study, no sample below 5 mg/dl (phenotype DD) was found. Mean plasma apo H levels in NN and ND groups were 22.1 + 1.6 mg/dl and 12.5_+ 1.6 mg/dl, respectively. The gene frequencies of Bg N and Bg D in a Japanese population were 0.957 and 0.043, respectively. These results were similar to gene frequencies of Bg ~ and Bg D in Caucasoids.
A 66‐year‐old man was admitted with visual impairment, functional disability, and worsening glycemic control. On admission, he had optic atrophy without diabetic retinopathy in both eyes, sensory impairment of the lower extremities, ataxia, and cognitive impairment. As both serum and cerebrospinal fluid tested positive for syphilis, he was diagnosed with neurosyphilis and treated with antibiotics. Functional ability and cognitive function improved after conducting syphilis treatment; we consequently started him on an insulin self‐administration program. Two years later, his glycemic control has normalized. Dementia caused by neurosyphilis is one of the most important differential diagnoses of treatable dementia; hence, early diagnosis and early treatment are important.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.